Navigation Links
Misonix Announces New Sales Agency Agreement for Eastern Europe
Date:3/3/2009

FARMINGDALE, N.Y., March 3 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has entered into a new, two year, sales agency agreement with privately-held Advanced Oncology Systems ("AOS"), based in Wuppertal, Germany, for the representation of the Sonablate(R) SB500 High Intensity Focused Ultrasound ("HIFU") System, the SonaStar(TM) Ultrasonic Surgical Aspiration System, the BoneScalpel(TM) Ultrasonic Bone Cutting System, and the SonicOne Ultrasound Cleansing & Debridement System.

AOS has extensive experience with capital equipment sales, with special emphasis in cancer therapy and neurosurgery. The agreement provides AOS with the rights to sell in most Eastern European countries, with a primary focus in Hungary, Poland, Romania, Bulgaria, the Russian Federation, Ukraine, and Georgia. Sales will be consummated primarily through specialty distributors; however, in certain instances, direct to hospital sales are permitted. Minimum sales performance criteria for each product platform are stipulated in the agreement.

The Sonablate is a state of the art High Intensity Focused Ultrasound ("HIFU") instrument used for the trans-rectal ablation of tumors of the prostate gland. Characteristics of HIFU, when used for this purpose, are clinical outcomes similar to other treatment modalities, but with low instances of urinary incontinence and sexual impotence.

The SonaStar is used by Neuro and General Surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels. In addition, OsteoSculpt(TM) bone shaving technology can be employed with the SonaStar to safely remove osseous structures, thus providing acces
'/>"/>

SOURCE Misonix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Misonix Announces New Distribution Agreement for Israel
2. Misonix Reports Earnings and Increased Revenues for the Three and Six Months Ended December 31, 2008
3. Misonix Schedules Second Quarter Fiscal Year 2009 Financial Results Conference Call; February 9, 2009 at 4:30 P.M. Eastern
4. Misonix Announces New HIFU Distribution Agreement for Italy
5. Misonix Announces Extension and Expansion of Distribution Agreement With Mentor Corporation
6. Misonix Reports First Quarter Fiscal Year 2009 Financial Results
7. Misonix Schedules First Quarter Fiscal Year 2009 Financial Results Conference Call; November 13, 2008 at 4:30 P.M. Eastern
8. Misonix Subsidiary, Sonora Medical Systems, Announces a Major Ultrasound Probe Study
9. Misonix To Present at The Rodman & Renshaw 10th Annual Healthcare Conference
10. Cambridge Healthtech Institute Announces Its Premiere Collaborative Innovation in Biomedicine Conference
11. Boston Scientific Announces Japanese Launch of Taxus(R) Liberte(R) Drug-Eluting Stent System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... Is Colorado’s legal cannabis industry the victim of ... will mark the 18-month milestone of its historic experiment ... Colorado’s legal marijuana industry has been successful and has ... some new challenges. , For example, many marijuana retailers ... the wake of last month’s “420” cannabis celebrations. And ...
(Date:5/6/2015)... 2015 Inversion Studios, a full-service ... and Pilates classes, provides personalized individual instruction and ... with its new Pilates Ring magic circle. , ... leaner, stronger, more centered and graceful, Inversion Studios ... venue to healthy fitness through yoga and Pilates. ...
(Date:5/6/2015)... Texas (PRWEB) May 06, 2015 vcfo, ... finance, HR, IT and operational support to optimize business ... Consulting CFOs, Jack Lynch and Michael Scheaffer. Both Lynch ... finance and leadership experience. , “We are delighted ... Ellen Wood, vcfo CEO. “Leveraging their background in financial ...
(Date:5/6/2015)... 2015 Wolters Kluwer , a ... students, announced today that in a survey of nearly ... of the clinical decision support resource improves the quality ... 2014, UpToDate users in more than 170 countries worldwide ... on average. In Germany alone, 95% of all university ...
(Date:5/6/2015)... Anitoa Systems, (“Anitoa”), a Palo Alto ... of China, has successfully demonstrated a handheld real time ... Anitoa’s handheld qPCR is shown to be capable ... including hepatitis B, C, and E. Coli. This qPCR ... sample and over 9 orders of magnitude dynamic range. ...
Breaking Medicine News(10 mins):Health News:As Colorado Faces Regional Shortages, Cannabis CEO Says Marijuana Will Eventually Be Traded like Any Other Commodity 2Health News:As Colorado Faces Regional Shortages, Cannabis CEO Says Marijuana Will Eventually Be Traded like Any Other Commodity 3Health News:Inversion Studios’ New Pilates Ring Is Circle of Magic for Body, Mind and Spirit 2Health News:Inversion Studios’ New Pilates Ring Is Circle of Magic for Body, Mind and Spirit 3Health News:vcfo Adds Two Senior Executives to Growing Team 2Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 2Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 3Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 2Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 3
... NAPA, Calif., April 15 Senetek PLC (OTC,Bulletin Board: ... technologies that target the science of healthy aging, announced ... 2007., Revenue for the year ended December 31, ... for the fourth quarter of 2007,were $223,000, compared with ...
... 15 The Joint Center for,Political and Economic ... of health in order to reduce disparities and ... linked to,socioeconomic status," said Ralph B. Everett, the ... determinants, most health,inequities are avoidable," he added., ...
... a new study to evaluate the impact of a ... Presented at the American Association of Cancer Research Annual ... tracking system is key to improving rates of medical ... eliminating racial disparity in treatment. , Women who ...
... many with the autoimmune disease, researchers say , , TUESDAY, April ... the number of attacks in people with multiple sclerosis appears ... The pill was effective in preventing relapses in more than ... years, according to research that was expected to be presented ...
... Council (ACC) supports the rigorous scientific evaluation process,of ... Evaluation of,Risks to Human Reproduction. Following an expert ... NTP Brief on bisphenol A affirms that,there are ... effects of,bisphenol A on human reproduction and development., ...
... their names to ghost-written studies that exaggerated painkiller,s ... Industry documents reveal that pharmaceutical giant Merck & ... Vioxx research published in top medical journals while ... controversial cox-2 painkiller. , The company apparently also ...
Cached Medicine News:Health News:Senetek PLC Reports 2007 Financial Results 2Health News:Senetek PLC Reports 2007 Financial Results 3Health News:Joint Center Sees Social Determinants of Health as Key to Reducing Disparities at Annual Fund-raising Gala 2Health News:Tracking and feedback registry helps reduce disparities in breast cancer care 2Health News:Pill Reduces Relapses in MS Patients 2Health News:Draft National Toxicology Program Report Supports Safety of Bisphenol A 2Health News:Key Vioxx Research Was Written by Merck, Documents Allege 2Health News:Key Vioxx Research Was Written by Merck, Documents Allege 3Health News:Key Vioxx Research Was Written by Merck, Documents Allege 4
(Date:5/6/2015)... 2015 NxStage Medical, Inc. (Nasdaq: NXTM ... reported first quarter financial results that exceed the top ... for the first quarter of 2015 increased 10 percent ... for the first quarter of 2014. The Company,s revenue ... to $78.5 million.  The increase was driven by outperformance ...
(Date:5/6/2015)... , May 6, 2015  IGI Laboratories, Inc. (NYSE-MKT: IG), ... pharmaceutical company, will be presenting today at the Deutsche Bank ... on May 6 th and 7 th at ... Jason Grenfell-Gardner , CEO and President and ... will present today, May 6, 2015, at 3:30 p.m. ET.   ...
(Date:5/6/2015)...  Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ) ("Juniper" ... three-month period ended March 31, 2015. First quarter financial highlights ... increase of 19% as compared to $7.0 million in ... increased 41% year-over-year, enabled by the return of normalized ... in the fourth quarter of 2014; , Service ...
Breaking Medicine Technology:NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 2NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 3NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 4NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 5NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 6NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 7NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 8NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 9NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 10NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 11Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 2Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 3Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 4Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 5Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 6Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 7Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 8Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 9Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 10Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 11
... Data presented yesterday showed that USL255, a novel ... less fluctuation in topiramate plasma levels than immediate-release ... These and other findings from the USL255 early ... the 64th annual American Epilepsy Society (AES) meeting ...
... Dec. 6, 2010 The Novartis Pharmaceutical Corporation ... disease control and tumor reduction in extensively pretreated ... become refractory after an autologous stem cell transplant, ... clinical trial presented today(1). In this ...
Cached Medicine Technology:Data Suggests Positive Pharmacokinetic Results From Phase I Research of Extended-Release Topiramate 2Data Suggests Positive Pharmacokinetic Results From Phase I Research of Extended-Release Topiramate 3Data Suggests Positive Pharmacokinetic Results From Phase I Research of Extended-Release Topiramate 4Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 2Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 3Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 4Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 5Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 6Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 7
... Sterile E*Kits® can be a valuable ... care; when the items necessary for a ... facility protocols and continuum of care are ... are packaged in sequence of use, allowing ...
... trays to dry trays to specialty vaginal ... Cardinal Health offers the widest offering in ... components that are proven to be safe ... of surgical site infections. Cardinal Health Scrub ...
The applicator is designed for a smooth delivery of the solution for surgical procedures....
... Panel consists of plasma specimens with reactivity ... antibodies to HTLV I and II. This ... and diagnostic laboratories to evaluate their anti-HTLV ... test systems are included for comparative analysis ...
Medicine Products: